High-frequency oscillatory ventilation (HFOV) can improve ventilation-perfusion matching without excessive alveolar tidal stretching or collapse-reopening phenomenon. This is an attractive feature in the ventilation of patients with ARDS. However, two recent large multi-center trials of HFOV failed to show benefits in this patient population. The following review addresses whether, in view of these trails, HFOV should be abandoned in the adult population? Key words: acute respiratory failure; high-frequency oscillatory ventilation. [Respir Care 2016;61(6):791-800.
Introduction
In 1967, Ashbaugh et al 1 published a case series describing a common constellation of symptoms in 12 patients with acute onset respiratory distress. The patterns, which the authors coined "respiratory-distress syndrome," included: tachypnea, lung compliance reduction, cyanosis refractory to oxygen therapy, and diffuse alveolar infiltrates on chest roentgenogram. 1 This syndrome, since retermed ARDS, has undergone periodic redefinition. In the most recent terminology, the Berlin definition 2 categorizes ARDS based on the severity of hypoxia as defined by the P aO 2 /F IO 2 ratio at a PEEP Ն5 cm H 2 O. Mild is defined as P aO 2 /F IO 2 Յ300 mm Hg, moderate is defined as P aO 2 /F IO 2 Յ200 mm Hg, and severe is defined as P aO 2 /F IO 2 Յ100 mm Hg. Included in the criteria was the occurrence of worsening respiratory symptoms within 1 week of a known insult and bilateral opacities on chest imaging. Cardiac failure is now recognized to be a potential contributor to the development of ARDS. With the changes in definitions, the hope is to better identify and treat the syndrome.
The severe inflammatory process and diffuse endothelial and epithelial injury associated with ARDS can lead to poor outcomes. The mortality of ARDS is related to the degree of the hypoxia. With severe ARDS, mortality can be as high as 45%. 2 Those who do survive ARDS can continue to have significant functional disabilities long after discharge from the hospital. In a prospective cohort study, 109 young (average age 45 y old) ARDS survivors were followed up to 5 y following their discharge from the ICU. 3 Depression, posttraumatic stress disorder, and persistent weakness were common features in the cohort. Many of these subjects developed pulmonary fibrotic changes that were in line with ventilator-induced lung injury (VILI).
It has been recognized that mechanical ventilation can further exacerbate (or even precipitate) ARDS. Past mechanical ventilation strategies favored large tidal volumes (V T ) of up to 12-15 mL/kg and tolerating end-inspiratory plateau pressures in excess of 35 cm H 2 O in an attempt to improve oxygenation. 4 Toward the start of the new millennium, however, there was increasing recognition that this strategy induced significant alveolar injury VILI. The mechanisms of VILI are complex but revolve around the concepts of regional alveolar overstretching and collapsereopening phenomenon.
The publication of the large National Institutes of Health ARDS Network trial in 2000 5 led to significant changes in the ventilation management of patients with ARDS. From this study, targeting V T in the normal physiologic range of 4 -8 mL per kg ideal body weight and limiting plateau pressures to the normal physiologic maximum of 30 cm H 2 O resulted in a 22% reduction in mortality compared with subjects who were ventilated with large V T . 5 The mortality benefits of this lung-protective strategy were further supported by a 2013 Cochrane review. 6 The Conceptual Rationale for Using HFOV High-frequency oscillatory ventilation (HFOV) is a ventilator support strategy that, in the adult, uses breathing frequencies of 180 -900 breaths/min (3-15 Hz) with resulting small V T , often less than anatomic dead space. [7] [8] [9] HFOV provides an oscillating pressure/volume waveform superimposed on a constant distending mean airway pressure (P aw ). With this pattern, HFOV can deliver a substantial P aw to improve ventilation-perfusion matching without excessive alveolar tidal stretching or collapse reopening phenomenon. This is an attractive concept that specifically addresses VILI risk factors 10 (Fig. 1) .
HFOV is usually provided with a closed ventilator system and relies on a set bias flow to deliver fresh gas and remove carbon dioxide from the circuit. Unlike conventional mechanical ventilation, both the inspiratory and expiratory phases are active processes. P aw is generated by manipulations of the bias flow and circuit pressure. It is often initially set 5 cm H 2 O above the patient's P aw while on conventional ventilation and adjusted to meet oxygenation goals. 11 The oscillatory pressure swings (and thus V T ) of HFOV are generally provided by a piston whose displacement is clinician-set. The oscillating pressures in the circuit are significantly damped in alveolar regions. Indeed, the impedance in the endotracheal tube alone significantly reduces the pressure swings in the trachea to 5-16% of that in the circuit. 12 As a consequence, the actual pressure swings and V T delivered to the alveoli are markedly less than in the circuit. The oscillatory pressure swings and V T can be increased by increasing the oscillator displacement (power setting), decreasing the oscillation frequency (longer inspiratory displacement time), increasing the internal diameter of the endotracheal tube, or reducing the inspiratoryexpiratory ratio. 12 Because the V T levels actually reaching alveoli are usually less than dead space, HFOV relies on various mechanisms for gas exchange through the airways. 13,14 Similar to conventional ventilation, inspired oxygen can travel as a bulk flow and reach proximal alveoli. Longitudinal dispersion occurs by combined convective flow and diffusion. Pendelluft arises from different alveolar emptying time and adjacent ventilation of nearby alveoli, resulting in asynchronous alveolar gas filling. Gas mixing at the smallest bronchioles occurs by molecular diffusion. Gas movement due to asymmetric velocity profiles occurs due to slower velocities along the wall of the airway compared with the center. With repeated oscillations, the center gas moves to the distal lung units, whereas the gas along the wall moves proximally. 14 The heart also plays a role in gas exchange by cardiogenic mixing. Although the bias flow is important in CO 2 removal, the frequency, inspiratory time, and oscillatory volume are the predominant contributors to the rate of CO 2 elimination. 12,15-18 Fig. 1 . Schematic drawing to illustrate the position of the dynamic loops in relation to the overall pressure-volume curve during highfrequency oscillatory ventilation before and after sustained inflation. From Reference 9, with permission.
Numerous small animal studies in the last half of the 20th century were important in elucidating the mechanisms of HFOV support, and these prompted the performance of numerous clinical trials. 19 These were first performed in neonatal/pediatric populations starting in the 1970s, and subsequent meta-analyses suggested that HFOV use was associated with a significantly lower incidence of chronic lung disease. 20 Application of HFOV in the adult population for ARDS required the development of more powerful devices and was first described in 1997. 21 A subsequent meta-analysis of several small adult trials in 2013 suggested that HFOV may actually offer a mortality benefit. 22 However, times have changed. Several new and larger trials have called into question these optimistic reports, and indeed, the role of HFOV, especially in the adult, is undergoing careful reconsideration. The sections below look at both sides of this important clinical question.
The Argument for Abandoning HFOV in the Adult

Pathophysiology Considerations
Most of our understanding of HFOV has come from small animal models and the neonatal/pediatric population, and these concepts may not apply to the much larger adult lung. 23 Moreover, in some of these animal studies, potential harmful effects of HFOV were observed. For example, in canine models, significant regional differences were seen in alveolar pressure at various locations in the lungs despite having mean alveolar pressure nearly equal to the mean opening airway pressure. This resulted in the observation of distinct areas of both hyperinflation and hypoinflation. 24 In an adult sheep model, Sedeek et al 26 used adult highfrequency oscillatory ventilator management strategies that were identical to the ones used in early adult clinical trials by Fort et al 21 and Mehta et al. 25 These investigators found that quite large V T (ie, 6 mL/kg) were being delivered into the proximal airways. The authors believed that the larger endotracheal tubes used in adults may have provided less attenuation of the oscillating pressures in HFOV compared with pediatric size endotracheal tubes. 26 As a result, the alveoli could be overdistended and injured from large pressure swings. However, caution must be exercised to avoid overinterpreting these data because, as noted above, considerable damping of the circuit pressure and volume swings occurs in the more distal tracheobronchial tree.
As discussed earlier, improvements in the P aO 2 /F IO 2 with HFOV are dependent on providing pressure above the critical opening pressure of the alveoli and maintaining pressures above this threshold to minimize cyclical opening and closing of alveoli that leads to VILI. 10 However, this is not always the case. Papazian et al 27 compared HFOV in both the supine and prone position with prone-conventional ventilation targeting V T of 6 mL/kg in subjects with moderate ARDS. There was no significant improvement in the P aO 2 /F IO 2 at 12 h in the supine HFOV arm, whereas both the prone conventional ventilation and prone HFOV groups showed a significant improvement (from 138 Ϯ 58 to 217 Ϯ 110 mm Hg [P Ͻ.001] and from 126 Ϯ 40 mm Hg to 227 Ϯ 64 mm Hg [P Ͻ.001], respectively) at 12 h. Bronchoalveolar lavage was done before and 12 h after randomization. In both HFOV groups, cytokine interleukin-8 increased significantly from baseline levels as well as compared with the prone conventional ventilation arm. The prone conventional ventilation arm saw a decrease in concentration compared with its baseline level. The neutrophil concentration was lower in the prone conventional ventilation group compared with both HFOV groups. This study suggests that HFOV subjects alveoli to harmful cyclical opening and closing as interleukin-8 is up-regulated when epithelial cells are subjected to cyclical overstretching.
Conventional mechanical ventilation can often achieve improvements in P aO 2 /F IO 2 similar to HFOV, depending upon settings. For example, in rabbit lung injury models, utilizing a short lung recruitment maneuver followed by V T Ͻ5 mL/kg and PEEP adjusted to be above the lung's critical closing pressure was found to improve the P aO 2 /F IO 2 similar to HFOV. In addition, lung histology in this group showed minimal airway injury. 9 This was also supported by the work of Vazquez de Anda et al 28 in rats where high PEEP and low V T improved oxygenation but also reduced the influx of alveolar proteins as compared with HFOV.
Right ventricular dysfunction is a known complication of ARDS, and the high P aw and general absence of spontaneous inspiratory efforts during HFOV can exacerbate this problem further, especially under fluid-depleted conditions. Guervilly et al 29 evaluated right-ventricular function using transesophageal echocardiography in adult subjects with moderate to severe ARDS receiving HFOV. At baseline, over half of their subjects had right-ventricular dysfunction (defined by a right-ventricular end-diastolic area to left-ventricular end-diastolic area ratio Ͼ0.6), and 25% had right-ventricular failure (defined by right-ventricular end-diastolic area/left-ventricular end-diastolic area Ͼ0.9). Increasing the P aw Ͼ5 cm H 2 O to improve the P aO 2 /F IO 2 was found to worsen the right-ventricular enddiastolic area/left-ventricular end-diastolic area by as much as 40%. Cardiac index was also found to be significantly reduced due to increasing P aw and worsening right-ventricular function. As a consequence, vasopressor requirements may be higher in HFOV patients. These hemodynamic issues are important, given that death associated with HFOV appears to be more related to end-organ failure and hemodynamic compromise as opposed to failure to oxygenate. 30 High-frequency oscillatory ventilation requires synchrony with any existing patient breathing efforts. Spon-taneous respiration results in a reduced airway pressure that the ventilator may interpret as a circuit disconnect, subsequently stopping ventilation. 26 In addition, inadequate synchrony results in oxygen desaturation, patient discomfort, and barotrauma. To achieve synchrony, heavy sedation and the use of continuous neuromuscular blockade are often required. Indeed, in most of the clinical trials described below, the sedation needs and requirements for neuromuscular blockade were almost always higher in the HFOV group versus the control group.
Outcome Data From Randomized Clinical Trials
Although several small trials of HFOV versus conventional ventilation showed promise, 22 recently, 2 large trials have been published that have concluded no benefit and possibly harm with the use of HFOV.
The OSCILLATE and OSCAR trials were 2 large multicenter trials published in 2013 comparing HFOV with conventional mechanical ventilation in moderate to severe ARDS. In the OSCILLATE trial, 31 subjects of similar severity of ARDS were included (P aO 2 /F IO 2 of 113 Ϯ 38 mm Hg in the conventional ventilation group and 113 Ϯ 37 mm Hg in the HFOV group); however, subjects who had been ventilated for Ͼ72 h were excluded. The OSCAR trial 32 included subjects ventilated up to 7 d with similar ARDS severity; 114 Ϯ 38 mm Hg versus 121 Ϯ 46 mm Hg in conventional ventilation versus HFOV groups, respectively. Rather surprisingly, the OSCILLATE trial was prematurely stopped due to worse outcomes in the HFOV group. The mortality in the HFOV group was higher both for in hospital (47% vs 35%) and at 28 d (40% vs 20%). Although the conventional ventilation group had a higher number of subjects with refractory hypoxemia, the overall percentage of subjects dying due to this was similar between the groups. The OSCAR trial was completed as intended; however, it demonstrated no difference in mortality between the 2 groups (41.7% for HFOV vs 41.1% for conventional ventilation).
Interestingly, the mortality in the conventional ventilation strategy with OSCAR was much higher than the conventional ventilation group in OSCILLATE, despite the fact that the disease severity in the OSCILLATE group was higher (Acute Physiology and Chronic Health Evaluation [APACHE] II score 29 Ϯ 7 vs 21.7 Ϯ 6.1). An explanation for the mortality difference may lie in the manner in which the conventional groups were ventilated. The OSCILLATE conventional group received lower V T of 7.1 Ϯ 1.8 mL/kg, whereas the OSCAR conventional ventilation subjects had on average higher V T of 8.3 Ϯ 3.5 mL/kg. This supports the notion that lower V T ventilation conveys a survival advantage in moderate to severe ARDS and suggests that a significant mortality difference favoring conventional ventilation might have been seen in the OSCAR trial if the conventional ventilation arm used lower V T . A more recent meta-analysis that included these new trials has now concluded that there is no benefit to HFOV in the adult. 33 So why are the results of these more recent trials at odds with previous animal and pediatric data? Perhaps there are effects of HFOV in the adult lung that have not been fully appreciated in the past. High distending pressures are known to put the lung at risk for injury and cardiac compromise, and thus the very mechanism that improves P aO 2 /F IO 2 with HFOV may contribute to harm. Moreover, in ARDS, the lungs are affected in a heterogeneous manner, with areas of damaged and collapsed alveoli intermixed with open alveoli. High intrathoracic pressures may thus lead to further regional lung injury. HFOV settings in adults are also different from those of pediatric patients. Lower frequencies (4 -8 Hz in adult vs 8 -12 Hz in pediatric patients) and pressure amplitudes of up to 60 cm H 2 O are often used in adults. 34 This can translate into larger delivered V T in the adult. In a retrospective analysis of 156 subjects, Mehta et al 25 observed that Ͼ20% of their subjects developed pneumothoraces on HFOV while noting that barotrauma rates in conventional mechanical ventilation ranged from 7 to 14%. In the OSCILLATE trial, 18% in the HFOV arm developed new barotrauma after being switched from conventional ventilation. 31 As noted above, the need for sedation and neuromuscular blockade when using HFOV in the adult could also contribute to adverse outcomes. In the Multi-Center Oscillatory Ventilation for Acute Respiratory Distress Syndrome Trial (MOAT), 35 all subjects in the HFOV arm were paralyzed as well as 90% of the cohort in the study by Mehta et al. 25 In the OSCAR trial, over half in the HFOV group required neuromuscular blockade, which was more than the conventional group, and required paralysis on average half a day longer than the control group. 32 In the OSCILLATE trial, significantly more subjects in the HFOV arm required paralysis (83% vs 43%) for an average of 3 d, which is 1 d longer than the control. 31 In summary, HFOV should provide an ideal mode of ventilation for diffuse lung injury. However, this has not been the case in the adult population. This may be due to poorly understood effects of the HFOV ventilator pattern on injured lung units. It may also reflect cardiovascular effects as well as the need for excessive sedation, vasopressors, and neuromuscular blockade agents. Regardless, because there is no clear survival benefit and a possible higher risk for harm, a strong argument can be made that HFOV should not be used for adults with ARDS.
The Argument for Keeping HFOV as a Viable
Option in Adults With Severe ARDS
Conceptual Arguments Remain Attractive and Are Supported By Data
The conceptual lung-protective benefits of HFOV have been supported by numerous animal studies. 19,36 A particularly interesting report is that of Goddon et al, 37 who obtained static pressure-volume curves in anesthetized sheep before and after saline-induced lung injury. The authors measured changes in P aw with oxygenation and compared it with the static pressure-volume curve. They found that the P aw above the lower inflection point resulted in improvements in oxygenation and reached an optimum level when the P aw approached the upper inflection point. They did not find any further benefit in oxygenation with going beyond the upper inflection point. Going beyond this point, they concluded, was where alveoli distention occurred. This has been seen in other studies and supported with computed tomographic imaging. [38] [39] [40] Data from extensive studies in rabbits by several authors have also been enlightening. Injured rabbit lungs ventilated with HFOV demonstrated that increases in P aw resulted in linear oxygenation improvements with lung volume expansion. Bronchoalveolar lavage samples from these lung-injured rabbit models were found to have lower concentrations of polymorphonuclear neutrophils and less expression of inflammatory markers, such as tumor necrosis factor-␣ prostaglandins and platelet-activating factors, compared with conventional mechanical ventilation. 41, 42 Perhaps more importantly, a series of rabbit experiments by Froese and Bryan 36 consistently showed improved survival with HFOV. As we slowly unravel all of the mechanisms of VILI, the concepts underlying HFOV applications remain attractive.
Positive Results Have Consistently Been Reported in Infant/Pediatric Trials and Small Adult Studies
Multiple trials of HFOV in infant/pediatric populations have consistently shown that HFOV can be safely applied and is generally associated with improved longterm outcomes (ie, bronchopulmonary dysplasia and chronic lung disease). 20, 43 Admittedly, a few trials are negative, but only one, the HIFI trial, actually suggested harm from HFOV. 20 This trial, however, has been heavily criticized because of its unfamiliar devices and strategies, minimizing rather than optimizing mean airway pressure. A recent meta-analysis has concluded that HFOV use is associated with important clinical end points in neonatal/pediatric subjects.
There is much less experience with HFOV in adults than in infant/pediatric populations because devices powerful enough to provide effective gas exchange in adults took longer to develop. There is no question that HFOV in adult respiratory failure has the ability to improve oxygenation. Multiple retrospective studies have observed this phenomenon. 25,43,44 Mehta et al 25 found a 70% improvement in oxygenation with the initiation of HFOV for severe ARDS. Randomized trials also supported this observation. The MOAT trial saw the P aO 2 /F IO 2 35 Whether these gas exchange improvements translate into improved outcomes remains controversial. Small randomized controlled trials have attempted to answer this question with equivocal results. Until 2013, the MOAT trial 35 was the largest randomized controlled trial and demonstrated a 30-d mortality of 37% for HFOV versus 52% for the conventional ventilation arm. However, this difference was considered nonsignificant (P ϭ .10). As noted above, when taken together, a meta-analysis of these small pre-2013 trials suggested a mortality benefit to HFOV. 22 A common concern in these trials was that the conventional ventilation comparison group was usually not managed in a true lung-protective management algorithm. Nevertheless, the concept that HFOV could be effective in severe ARDS has some reasonably supportive clinical data.
Arguments to Abandon HFOV Focus Heavily on OSCAR/OSCILLATE, Both Flawed Trials
As noted above, HFOV settings are often counterintuitive; CO 2 clearance is driven largely by the power setting and is actually a function of the inverse of frequency (lower frequencies result in larger V T with HFOV devices). Moreover, oxygenation depends on high constant distending pressures that can seriously impair cardiac filling and increase right-ventricular afterload. These features demand experienced operators who have a good understanding of pulmonary physiology, cardiopulmonary interactions, and the operational characteristics of the HFOV device.
Unfortunately, in both the OSCAR and OSCILLATE trials described above, 31,32 many centers were involved that had only limited HFOV experience. Although both studies claim to have trained leadership personnel in all sites, the necessary 24/7 coverage by experts was often lacking. OSCAR was further hampered by the use of a new HFOV device that very few had ever operated before. This inexperience problem may have had even more impact in OSCILLATE, where Ͼ70% of the population was in shock at study entry and mean airway pressures were suddenly increased in the HFOV group from 20 to Ͼ30 cm H 2 O. Interestingly, despite this dramatic increase in P aw , HFOV subjects in OSCILLATE did not have a change in central venous pressure from pre-randomization values suggesting preload impairment. The mixture of high mean airway pressures, poor cardiac function, and inexperienced clinicians probably had serious consequences. Taken together, the inexperience in these 2 trials, coupled with the challenges of new devices and hemodynamically compromised subjects, undoubtedly contributed to many of the adverse outcomes. It is important to remember that a clinical trial of a device requires optimal operation of the device and is thus orders of magnitude more complex to accomplish than a simple drug versus placebo clinical trial.
Both OSCAR and OSCILLATE also recruited subjects for whom HFOV was probably not needed. Bollen et al, 45 in a review of infant/pediatric HFOV studies done over the last few decades, nicely demonstrated that as conventional lung-protective strategies were being introduced, the benefits to HFOV in clinical trials became less. This would suggest the HFOV probably adds little to effective conventional lung-protective ventilator support. Rather, HFOV should be considered a strategy to extend lung-protective support to sicker patients unable to be safely supported with conventional ventilation. HFOV logically should thus be reserved for those patients not in whom conventional ventilation is working, but in whom conventional ventilation is failing. In both OSCAR and OSCILLATE, the average entry P aO 2 /F IO 2 was well over 100, which translates into a P aO 2 of Ͼ60 mm Hg with an F IO 2 of Ͻ0.6, both in the setting of plateau pressures well below 30 cm H 2 O, clearly acceptable parameters for effective lung-protective ventilation. Indeed, in OSCILLATE, the included population was actually more of a hemodynamically compromised population than a respiratory failure population. Exposing patients properly supported safely with conventional ventilation to HFOV is not likely to provide much benefit and, as noted above, could cause harm in the wrong hands (and probably did).
This selection process was even further complicated in OSCILLATE, where 72 subjects were excluded because their physicians felt that HFOV was required and randomization would be unethical. Thus, the very patients these trials should have studied were systematically excluded. Finally, the crossover process confuses interpretation. In OSCILLATE, 31 subjects were switched from conventional ventilation to HFOV, presumably because they were failing conventional ventilation. Because it was an intention-to-treat analysis, any benefit of HFOV in these subjects would have improved conventional ventilation outcomes.
Taken together, these concerns cast serious doubt on the generalizability of OSCAR and OSCILLATE to most ICU settings managing patients with severe ARDS. Abandoning HFOV based solely on these results seems premature.
If HFOV Still Has a Role, When and How Should It Be Used?
For HFOV to be a safe and effective therapy in ARDS, it needs to be used in the right patient (severe hypoxemic respiratory failure, failing conventional ventilation), with the right expertise and device settings, and with the right hemodynamic monitoring/management strategy. Another important consideration is knowing when to stop HFOV as ineffective. In general, observational studies suggest that if HFOV is going to be effective, gas exchange improvements will occur over the first 6 -12 h. If this does not occur, the likelihood of HFOV success is low, and alternative rescue strategies, such as extracorporeal membrane oxygenation, should be considered.
Summary
Managing severe hypoxemic respiratory failure involves managing competing goals, supporting gas exchange while not harming the lungs or cardiovascular system. HFOV has theoretical beneficial features that might accomplish this, but outcome benefits, especially in the adult, have been difficult to demonstrate. Indeed, HFOV may actually be associated with harm in the adult. Whether this reflects inherent problems with the HFOV ventilator pattern or reflects poor management strategies in those using HFOV (or both) is unclear. Regardless, if HFOV is still to be considered a viable option, it should be reserved for those failing conventional ventilation and applied by clinicians with considerable experience with the device. 5 at Boston Children's in which there was no difference in any variable and in which they don't even tell you the actual pressures, volumes, or approach that was used in either group. They tell you the theoretical settings but they don't give you any actual data.
MacIntyre: Well, there are probably 20 trials in pediatric world. I wasn't prepared to review all of them.
Kacmarek: But there's not a trial in the neonatal world that shows change in mortality.
MacIntyre:
The most significant end-point in most of these trials -probably all of them -is development of chronic lung disease. Which I would interpret as less ventilator-induced lung injury.
Kacmarek: I would agree with you but if you look at the specific trials where that was the case, conventional mechanical ventilation was done in a non-lung protective approach. If you look at the more current trials where the conventional arm was the way you'd expect it to be you don't have the same level of chronic lung disease.
MacIntyre: Bollen et al 6 showed that over the life history of HFOV two big events came along: surfactant and lung-protective ventilation and both of those reduced the benefit of HFOV over conventional ventilation. I won't argue that.
Mireles-Cabodevila:
I have three issues with the trials -the first is the protocol. They did test it in some group of subjects in the OSCILLATE 2 trial and then applied it. However, especially with HFOV, it is not the mode but how you apply it; I think more work was needed to define the best protocol. The second is that the question they ask is not, 'does the oscillator work', but 'does it work in early ARDS overall'. These trials did not answer whether we should use HFOV as a rescue therapy. The trials were designed differently. The OSCAR 1 study was a pragmatic trial and had little exclusion criteria. A negative result in a trial with a pragmatic design doesn't mean the intervention is ineffective. If it was positive it would be very good. The OSCILLATE 2 trial is an explanatory trial, with more exclusion criteria and expert centers. A negative result in an explanatory trial means the intervention is not effective. However, in this trial the only thing all centers were experts on was lung-protective ventilation, the HFOV protocol was not universal to all centers. It takes time to master a protocol. I doubt we will have any further trials, although one on rescue HFOV in subjects who have refractory hypoxemia or dangerous ventilation may be helpful.
MacIntyre: That's where it ought to be used in my opinion. The Lachman approach strategy of opening the lung up as applied to that trial 7 I think was too aggressive, especially in a population when 2/3 were in shock. I think that's a bad combination.
We end up only using HFOV for patients who cannot go into ECMO. Which is where we were using it before.
Marini: Neil, very nice. An interesting side issue is that effective driving pressure should have been quite low in those HFOV trials. Was lung function actually deteriorating in the dying subjects? If HFOV was doing damage to the lung you would expect that oxygenation would be crashing, wouldn't you?
Macintyre: I hope I'm not misspeaking, but as I understand the Canadian group's explanation of why OSCIL-LATE 2 failed was hemodynamics.
Marini:
The other interesting thing to me, and I've never quite understood it, is the total minute ventilation that's moving in and out of the patient is high. Right?
MacIntyre: Well, the total ventilation moving in and out of the circuit and major airways is high. What's actually taking place at the alveolar level, I'm not sure anybody really knows.
Marini: No.
MacIntyre: It's very confusing because you can get large tidal pressure and volume swings in the circuit but at the alveolar level these swings are often quite small.
Marini: I'm thinking about the total minute ventilation coming in and out of the lungs and if that has any relation to dead space. Because if it does, then several things come to mind. The V D /V T ratio might be quite high in HFOV. People don't talk much about that.
MacIntyre: I'm not sure what deadspace means when dealing with nonconvective gas transport mechanism. You have important O 2 and CO 2 concentration gradients through the entire network of airways and these are involved in such things as Taylor dispersion, augmented diffusion and pedelluft. John, I'm not sure how to translate these concepts into dead space as it applies to bulk flow ventilation.
Marini: I raise it as a question.
MacIntyre: I don't have the answer.
Marini:
One last thing. If the alveoli are being ventilated more than usual, small V Ts but faster and being ventilated with a high V D /V T , the local epithelial pH should in that situation be extremely high. There are physiological studies done in the late '60s showing that if you do not add CO 2 to the inhaled airstream of an animal with high deadspace that is being relatively over ventilated, the lungs fall apart due to inflammation. There may be a lot of contributors here. We're thinking mechanical, and mechanically HFO should be good; but from the ventilation side and gas exchange side it might be inflicting damage or holding back progress.
MacIntyre: It very well could. As I'vethought about this over the years I've divorced myself form the notion of traditional ventilation at the alveolar level. I think this is CPAP with some funky ways of replenishing the
